NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 268)
Posted On: 03/23/2018 5:16:41 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Technology Mimics the Body’s Natural Creation of Pain Fighting Peptides
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is engaged in the development of pain relievers that mimic body’s natural pain relief peptides. An article discussing the company reads: “The linker technology that underlies PreveCeutical’s drug development platform was developed at the University of Queensland in Australia. At that impressive institution, Dr. Parekh headed a team that developed synthetic molecules capable of mimicking the endomorphins produced by the body for pain relief, as explained by PreveCeutical chairman and CEO Stephen Van Deventer in a recent video interview (http://nnw.fm/ZxAz9). Although they are as potent as morphine, the effect of these endomorphins is transitory, since they metabolize in seconds. However, Dr. Parekh’s linker technology stabilizes those molecules, allowing them to be used as drugs while maintaining and enhancing their efficacy.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is engaged in the development of pain relievers that mimic body’s natural pain relief peptides. An article discussing the company reads: “The linker technology that underlies PreveCeutical’s drug development platform was developed at the University of Queensland in Australia. At that impressive institution, Dr. Parekh headed a team that developed synthetic molecules capable of mimicking the endomorphins produced by the body for pain relief, as explained by PreveCeutical chairman and CEO Stephen Van Deventer in a recent video interview (http://nnw.fm/ZxAz9). Although they are as potent as morphine, the effect of these endomorphins is transitory, since they metabolize in seconds. However, Dr. Parekh’s linker technology stabilizes those molecules, allowing them to be used as drugs while maintaining and enhancing their efficacy.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)